Proposal Status/Commentary

After a standard is proposed in Pharmacopeial Forum (PF) for public comment, the assigned Expert Committee reviews the comments and determines whether to approve the standard as a Revision, defer or cancel the standard. USP posts the lists of Revisions, Deferrals, Cancellations, and Commentary for each Issue of USP–NF.

• Revisions are items that have been proposed in PF, were approved by the assigned Expert Committee, and will appear in the noted publication. These items will have corresponding Commentary (see below).
• Deferrals are items that have been proposed in PF but are not yet approved by an Expert Committee and remain in process. Items that have been deferred can be approved and published in a subsequent Issue of USP–NF. Some deferrals are later canceled.
• Cancellations are items that have been proposed in PF but will not move forward to ballot and subsequent publication. Canceled items may be re-proposed in a future PF.

Commentary is a summary of comments received and the assigned Expert Committee's responses. Commentary is published for Revisions only. In cases where proposals have been re-published in PF, only comments from the most recent PF publication are included in Commentary. Commentary is posted the same day the official text is published in USP–NF Online.

USP-NF 2026, Issue 5

• Commentary (posted 27-Mar-2026)

USP-NF 2026, Issue 4

• Deferrals (posted 29-Jan-2026)
• Cancellations- none
• Revisions (posted 29-Jan-2026)
• Commentary (posted 30-Jan-2026)
• Commentary for IRAs published in USP-NF 2026, Issue 4 (to be posted 30-Jan-2026)
  • Azeotropic Isopropyl Alcohol
  • Isopropyl Alcohol

USP-NF 2026, Issue 3

• Deferrals (posted 21-Nov-2025)
• Cancellations (posted 21-Nov-2025)
• Revisions (posted 21-Nov-2025)
• Commentary (posted 21-Nov-2025)
• Commentary for IRAs published in USP-NF 2026, Issue 3 (posted 21-Nov-2025)
  • Nefazodone Hydrochloride
  • Nefazodone Hydrochloride Tablets
  • Polyethylene Glycol 40 Castor Oil
  • Teriflunomide
  • Teriflunomide Tablets

USP-NF 2026, Issue 2

• Deferrals (posted 29-Aug-2025)
• Cancellations (posted 29-Aug-2025)
• Revisions (posted 29-Aug-2025)
• Commentary (posted 29-Sep-2025; updated 21-Nov-2025)

USP-NF 2026, Issue 1

• Deferrals (posted 30-Jun-2025)
• Cancellations (posted 30-Jun-2025)
• Revisions (posted 30-Jun-2025)
• Commentary (posted 25-Jul-2025; updated 03-Oct-2025)

USP-NF 2025, Issue 3 (currently official)

• Deferrals (posted 28-Mar-2025)
• Cancellations (posted 28-Mar-2025)
• Revisions (posted 28-Mar-2025)
• Commentary (posted 02-Jun-2025; revised 03-Oct-2025)

USP-NF 2025, Issue 2 

• Deferrals (posted 02-Dec-2024)
• Cancellations (posted 02-Dec-2024)
• Revisions (posted 02-Dec-2024)
• Commentary (posted 03-Feb-2025; updated 28-Mar-2025; updated 25-Apr-2025; updated 14-Oct-2025)

USP-NF 2025, Issue 1 

• Deferrals (posted 23-Jul-2024)
• Cancellations (posted 23-Jul-2024)
• Revisions (posted 23-Jul-2024)
• Commentary (posted 01-Nov-2024; updated 23-Jan-2025; updated 30-May-2025)

Previous USP-NF Issues

Interim Revision Announcements

IRAs published in 51(6)

No IRA proposals were published in PF 51(6)

IRAs published in 51(5)

• <89.1> Collagenase I
• Azeotropic Isopropyl Alcohol
• Isopropyl Alcohol

IRAs published in 51(4)

• Dapagliflozin Propanediol
• Desvenlafaxine Succinate
• Teriflunomide
• Teriflunomide Tablets

IRAs published in 51(3)

• Nefazodone Hydrochloride
• Nefazodone Hydrochloride Tablets
• Polyethylene Glycol 40 Castor Oil

IRAs published in 51(2)

• Magnesium Sulfate

IRAs published in 51(1)

No IRA proposals were published in PF 51(1)

Previous PF Issues